Document Type : Original Research


1 Student Research Committee, Faculty of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran

2 Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran



Background & Objective: This study aimed to determine the incidence of microRNA (miRNA; miR-1290) in the serum of oral squamous cell carcinoma (OSCC) patients compared to a control group using the qualitative real-time polymerase chain reaction (PCR) method.
Methods: Blood serum samples were obtained from patients diagnosed with OSCC and confirmed through biopsy. The samples were collected from patients referred to the Mashhad Dental Faculty and Ghaem Hospital. The OSCC group consisted of 17 patients, while the healthy group included 15 individuals. RNA was extracted from the patient samples, and samples with an A260/280 ratio between 1.8 and 2.0 (indicating acceptable RNA quality) were immediately converted into complementary DNA (cDNA) using albumin and cDNA reference genes. The SYBR green real-time reverse transcriptase PCR method was used to measure the presence of miR-1290 in the blood samples.
Results: A total of 32 patients were examined in this study, including 17 women (53.1%) and 15 men (46.9%). The mean age was 46.7 years in the healthy group and 54.6 years in the SCC group, indicating a significant difference (P<0.05). The expression level of the miR-1290 gene was higher in patients with SCC compared to the healthy group (P=0.000). While the expression level of miR-1290 was higher in grade 3 and advanced stage than in grades 2 and 1 and early stage, the differences were not statistically significant (P=0.173 and P=0.564 for grade and stage, respectively).
Conclusion: The expression level of miR-1290 may increase in SCC patients compared to healthy individuals, making it a potential circulating biomarker.  Further investigations for diagnostic utility would be warranted.


Main Subjects

  1. Johnson DE, Burtness B, Leemans CR, Lui VW, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. [DOI:10.1038/s41572-020-00224-3] [PMID]
  2. Rachagani S, Macha MA, Menning MS, Dey P, Pai P, Smith LM, Mo YY, Batra SK. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D; Pdx1-Cre mouse (KC) model. Oncotarget. 2015;6(37):40295. [DOI:10.18632/oncotarget.5641] [PMID]
  3. Amirkhah R, Schmitz U, Linnebacher M, Wolkenhauer O, Farazmand A. MicroRNA–mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromosomes Cancer. 2015;54(3):129-41. [DOI:10.1002/gcc.22231] [PMID]
  4. Wu B, Lei D, Wang L, Yang X, Jia S, Yang Z, Shan C, Yang X, Zhang C, Lu B. MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. Am J Cancer Res. 2016;6(6):1396.
  5. Sun C, Li J. Expression of MiRNA-137 in oral squamous cell carcinoma and its clinical significance. J Buon. 2018;23(1):167-72. [DOI:10.1155/2018/6514795] [PMID]
  6. Cai Z, Hao XY, Liu FX. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression. Arch Oral Biol. 2018;89:20-5. [DOI:10.1016/j.archoralbio.2018.01.016] [PMID]
  7. Cai Z, Hao XY, Liu FX. MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression. Arch Oral Biol. 2018;89:20-5. [DOI:10.1159/000479913] [PMID]
  8. Kim G, An HJ, Lee MJ, Song JY, Jeong JY, Lee JH, Jeong HC. Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer. 2016;91:15-22. [DOI:10.1016/j.lungcan.2015.11.013] [PMID]
  9. Li M, He XY, Zhang ZM, Li S, Ren LH, Cao RS, Feng YD, Ji YL, Zhao Y, Shi RH. MicroRNA-1290 promotes esophageal squamous cell carcinoma cell proliferation and metastasis. World J Gastroenterol: WJG. 2015;21(11):3245. [DOI:10.3748/wjg.v21.i11.3245] [PMID]
  10. Qin WJ, Wang WP, Wang XB, Zhang XT, Du JD. MiR-1290 targets CCNG2 to promote the metastasis of oral squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 2019;23(23).
  11. Xie R, Wu SN, Gao CC, Yang XZ, Wang HG, Zhang JL, Yan W, Ma TH. Prognostic value of combined and individual expression of microRNA-1290 and its target gene nuclear factor I/X in human esophageal squamous cell carcinoma. Cancer Biomark. 2017;20(3):325-31. [DOI:10.3233/CBM-170029] [PMID]
  12. Ghafouri-Fard S, Khoshbakht T, Hussen BM, Taheri M, Samadian M. A review on the role of miR-1290 in cell proliferation, apoptosis and invasion. Front Mol Biosci. 2021;8:763338. [DOI:10.3389/fmolb.2021.763338] [PMID]
  13. Guz M, Jeleniewicz W, Cybulski M. An insight into miR-1290: an oncogenic miRNA with diagnostic potential. Int J Mol Sci. 2022;23(3):1234. [DOI:10.3390/ijms23031234] [PMID]
  14. Lu J, Ma H, Lian S, Huang D, Lian M, Zhang Y, Huang J, Feng X. Clinical significance and prognostic value of the expression of LAMP3 in oral squamous cell carcinoma. Dis Markers. 2017;2017. [DOI:10.1155/2017/1218254] [PMID]
  15. Sun R, Wang X, Zhu H, Mei H, Wang W, Zhang S, Huang J. Prognostic value of LAMP3 and TP53 overexpression in benign and malignant gastrointestinal tissues. Oncotarget. 2014;5(23):12398. [DOI:10.18632/oncotarget.2643] [PMID]
  16. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857-66. [DOI:10.1038/nrc1997] [PMID]
  17. Huang X, Wang L, Liu W, Li FE. MicroRNA-497-5p inhibits proliferation and invasion of non-small cell lung cancer by regulating FGF2. Oncol Lett. 2019;17(3):3425-31. [DOI:10.3892/ol.2019.9954] [PMID]
  18. Imaoka H, Toiyama Y, Fujikawa H, Hiro J, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Mori T, Kato T, Toden S. Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann Oncol. 2016;27(10):1879-86. [DOI:10.1093/annonc/mdw279] [PMID]
  19. Sun B, Yang N, Jiang Y, Zhang H, Hou C, Ji C, Liu Y, Zuo P. Antagomir-1290 suppresses CD133+ cells in non-small cell lung cancer by targeting fyn-related Src family tyrosine kinase. Tumour Biol. 2015;36:6223-30. [DOI:10.1007/s13277-015-3307-4] [PMID]
  20. Lai XJ, Cheng HF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290. Eur Rev Med Pharmacol Sci. 2018;22(2).
  21. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. Serum miR-1290 as a marker of pancreatic cancer—response. Clin Cancer Res. 2013;19(18):5252-3. [DOI:10.1158/1078-0432.CCR-13-1899] [PMID]
  22. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, Goggins M. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013 1;19(13):3600-10. [DOI:10.1158/1078-0432.CCR-12-3092] [PMID]
  23. Henry NL, Hayes DF. Cancer biomarkers. Mol Oncol. 2012;6(2):140-6. [DOI:10.1016/j.molonc.2012.01.010] [PMID]
  24. Sun GG, Hu WN, Cui DW, Zhang J. Decreased expression of CCNG2 is significantly linked to the malignant transformation of gastric carcinoma. Tumour Biol. 2014;35:2631-9. [DOI:10.1007/s13277-013-1346-2] [PMID]
  25. Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX. Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. Nat Commun. 2016;7(1):11702. [DOI:10.1038/ncomms11702] [PMID]
  26. Li B, Wang F, Li X, Sun S, Shen Y, Yang H. Hsa_circ_0008309 may be a potential biomarker for oral squamous cell carcinoma. Dis Markers. 2018;2018. [DOI:10.1155/2018/7496890] [PMID]
  27. Geusau A, Borik‐Heil L, Skalicky S, Mildner M, Grillari J, Hackl M, Sunder‐Plassmann R. Dysregulation of tissue and serum microRNAs in organ transplant recipients with cutaneous squamous cell carcinomas. Health Sci Rep 2020;3(4):e205. [DOI:10.1002/hsr2.205] [PMID]
  28. Sun H, Wang L, Zhao Q, Dai J. Diagnostic and prognostic value of serum miRNA-1290 in human esophageal squamous cell carcinoma. Cancer Biomark. 2019;25(4):381-7. [DOI:10.3233/CBM-190007] [PMID]
  29. Nakashima H, Yoshida R, Hirosue A, Kawahara K, Sakata J, Arita H, Yamamoto T, Toya R, Murakami R, Hiraki A, Shinohara M. Circulating miRNA-1290 as a potential biomarker for response to chemoradiotherapy and prognosis of patients with advanced oral squamous cell carcinoma: A single-center retrospective study. Tumour Biol. 2019;41(3):1010428319826853. [DOI:10.1177/1010428319826853] [PMID]
  30. Baglio SR, Rooijers K, Koppers-Lalic D, Verweij FJ, Pérez Lanzón M, Zini N, Naaijkens B, Perut F, Niessen HW, Baldini N, Pegtel DM. Human bone marrow-and adipose-mesenchymal stem cells secrete exosomes enriched in distinctive miRNA and tRNA species. Stem Cell Res. 2015;6(1):1-20. [DOI:10.1186/s13287-015-0116-z] [PMID]
  31. Endzeliņš E, Berger A, Melne V, Bajo-Santos C, Soboļevska K, Ābols A, Rodriguez M, Šantare D, Rudņickiha A, Lietuvietis V, Llorente A. Detection of circulating miRNAs: comparative analysis of extracellular vesicle-incorporated miRNAs and cell-free miRNAs in whole plasma of prostate cancer patients. BMC Cancer. 2017;17(1):1-3. [DOI:10.1186/s12885-017-3737-z] [PMID